Well-established safety profile based on the largest lupus clinical trial program

BENLYSTA is the only biologic for lupus and lupus nephritis studied in over 7000 patients over 11+ years.

The safety profile of BENLYSTA has been established across a diverse patient population1-7

Icon: checkmark

Adults with lupus

Icon: checkmark

Children 5 years and older
with lupus

Icon: checkmark

Adults of Black race
with lupus

Icon: checkmark

Adults with lupus
nephritis

Icon: checkmark

Post-marketing safety trial
in adults with lupus

7000+
patients with lupus have been included in trials of BENLYSTA, including a clinical trial in patients with lupus nephritis (N=448)1-7

Lupus safety profile

The safety profile of BENLYSTA is well-established across clinical trials, including trials in IV and subcutaneous administration, and a long-term extension study.

IV formulation

Incidence of adverse reactions in IV trials (adult Phase II, BLISS-52, and BLISS-76)

In ≥3% of patients treated with BENLYSTA IV 10 mg/kg + ST and ≥1% more frequently than in patients receiving placebo + ST in the 52-week Phase II trial, BLISS-52, and BLISS-76

Adverse reactions BENLYSTA 10 mg/kg
(n=674)
Placebo
(n=675)
Nausea 15% 12%
Diarrhea 12% 9%
Pyrexia 10% 8%
Nasopharyngitis 9% 7%
Bronchitis 9% 5%
Insomnia 7% 5%
Pain in extremity 6% 4%
Depression 5% 4%
Migraine 5% 4%
Pharyngitis 5% 3%
Cystitis 4% 3%
Leukopenia 4% 2%
Gastroenteritis viral 3% 1%

Adverse reactions in the BLISS-LN and PLUTO trials were consistent with those in adult IV trials.

Adverse reactions in the EMBRACE trial were consistent with the known safety profile of BENLYSTA administered IV + ST in the overall population.7

BASE (post-marketing trial of 4003 adult patients) demonstrated rates of AEs consistent with the pivotal trials and higher rates of serious infusion/hypersensitivity reactions, fatal reactions, and serious psychiatric events.7

AE = adverse event; BASE = Belimumab Assessment of Safety in SLE; BLISS-LN = Belimumab International Study in Lupus Nephritis; EMBRACE = Efficacy and Safety of Belimumab in Adult Subjects of Black Race; IV = intravenous; PLUTO = Pediatric Lupus Trial of BENLYSTA; ST = standard therapy.

SC formulation

  • The safety profile was consistent with the known safety profile of BENLYSTA IV + ST, with the exception of local injection site reactions
    • Injection site reactions in BENLYSTA + ST group: 6.1%
    • Injection site reactions in placebo + ST group: 2.5%
    • Most common injection site reactions: pain, erythema, hematoma, pruritus, and induration

SC = subcutaneous.

Long-term safety results

Safety data observed over 7 years8

Long-term safety was assessed in the open-label BLISS-76 LTE (US participants only)

Primary endpoint (safety) results (N=268) (at any time post-baseline)
Most frequent AEs (≥25%)
Arthralgia 40.3%
Nausea 32.8%
Headache 32.1%
Infections
Bacterial upper respiratory tract infection 28.7%
Viral upper respiratory tract infection 28.4%
Bacterial urinary tract infection 26.1%
≥1 SAE 41.8%
≥1 severe SAE (grade 3 or 4 events listed as life-threatening) 37.3%
Discontinuation due to an AE 9.7%

Over the 7-year follow-up, the rate of treatment-emergent AEs remained stable.8

Results are descriptive. Exploratory results should be interpreted with additional care.
See study design for data limitations.

LTE = long-term extension; SAE = serious adverse event.

Lupus nephritis safety profile

Adverse events observed in BLISS-LN were consistent with the known safety profile of BENLYSTA IV in patients with lupus.

Incidence of adverse events in the 104-week BLISS-LN trial9

At least one, % CYC/AZA arm
  BENLYSTA IV + ST
(n=60)
Placebo + ST
(n=59)
AE 93.3% 91.5%
Related AE 58.3% 52.5%
Serious AE 30.0% 23.7%
Severe AE 26.7% 22.0%
AE resulting in IP discontinuation 13.3% 8.5%
On-treatment fatal serious AEs which resulted in death on or off treatment 1.7% 0%
Additional deaths occurring after the treatment period 0% 0%
At least one, % MMF arm
  BENLYSTA IV + ST
(n=164)
Placebo + ST
(n=165)
AE 96.3% 95.2%
Related AE 53.7% 53.3%
Serious AE 24.4% 32.1%
Severe AE 23.2% 21.2%
AE resulting in IP discontinuation 12.8% 14.5%
On-treatment fatal serious AEs which resulted in death on or off treatment 1.8% 1.8%
Additional deaths occurring after the treatment period 1.2% 1.2%
At least one, % Average across both arms
  BENLYSTA IV + ST (n=224) Placebo + ST
(n=224)
AE 95.5% 94.2%
Related AE 54.9% 53.1%
Serious AE 25.9% 29.9%
Severe AE 24.1% 21.4%
AE resulting in IP discontinuation 12.9% 12.9%
On-treatment fatal serious AEs which resulted in death on or off treatment 1.8% 1.3%
Additional deaths occurring after the treatment period 0.9% 0.9%
At least one, % CYC/AZA arm MMF arm Average across both arms
  BENLYSTA IV + ST
(n=60)
Placebo + ST
(n=59)
BENLYSTA IV + ST
(n=164)
Placebo + ST
(n=165)
BENLYSTA IV + ST (n=224) Placebo + ST
(n=224)
AE 93.3% 91.5% 96.3% 95.2% 95.5% 94.2%
Related AE 58.3% 52.5% 53.7% 53.3% 54.9% 53.1%
Serious AE 30.0% 23.7% 24.4% 32.1% 25.9% 29.9%
Severe AE 26.7% 22.0% 23.2% 21.2% 24.1% 21.4%
AE resulting in IP discontinuation 13.3% 8.5% 12.8% 14.5% 12.9% 12.9%
On-treatment fatal serious AEs which resulted in death on or off treatment 1.7% 0% 1.8% 1.8% 1.8% 1.3%
Additional deaths occurring after the treatment period 0% 0% 1.2% 1.2% 0.9% 0.9%

AZA = azathioprine; CYC = cyclophosphamide; IP = investigational product; MMF = mycophenolate mofetil.

Icon: Medical support

Adverse events in the BLISS-LN trial were consistent with those observed in adult IV trials conducted in patients with lupus

Learn more

BENLYSTA for lupus

BENLYSTA improved key clinical outcomes for appropriate patients.

Find out more

BENLYSTA for lupus nephritis

BENLYSTA improved key clinical outcomes for appropriate patients.

Find out more

Choose the well-established safety profile of BENLYSTA now

Choose the well-established safety profile of BENLYSTA now